Explore IDT’s customizable, high-performing cancer research solutions with flexible NGS workflows. From whole genome and exome to targeted sequencing, we support insights across solid tumors, liquid biopsy, MRD, and blood cancers. As your trusted partner, we help drive discoveries with tools designed for confident detection, monitoring, and analysis of cancer-related genetic changes—empowering your lab to advance cancer research.
IDT’s cancer research solutions empower confident insights for:
Solid tumor cancer research has greatly benefited from NGS, but challenges remain, such as low-input samples and cumbersome workflows. Overcome these challenges with IDT’s solutions for your lab’s unique insight and workflow needs.
Predesigned or custom panels to get the specific cancer insights you need with minimal sequencing resources used.
Comprehensive genomic profiling for solid tumors with content-flexible panels and genomic signature modules to optimize use of sequencing resources for your insight needs.
Whole exome, genome, transcriptome, and methylome sequencing components for broad solid tumor research insights.
Understand the hidden risks of overlooking comprehensive genomic signature assessments. VARIANTPlex™ solid tumor solutions, powered by Anchored Multiplex PCR (AMP™) and Archer® Analysis, deliver a comprehensive, automatable workflow for high-confidence genomic profiling.
Our workflows help researchers detect, monitor, and analyze cancer-related genetic alterations. From challenging samples to disease monitoring, IDT delivers flexible NGS solutions tailored to your lab’s evolving research needs.
Unlock superior performance with IDT’s xGen cfDNA/FFPE Kit and panels—higher on-target rates, better coverage, and lower duplication than leading workflows.
NGS has transformed blood cancer profiling, yet challenges persist including complex variant detection, labor-intensive workflows, and bioinformatics demands.
Discover important blood cancer research insights with workflows fit for your lab.
Hear from experts at Duke on their experience implementing Archer FUSIONPlex™ and VARIANTPlex™ custom NGS assays for profiling heme malignancies.
Interested in learning more about cancer research solutions?